Skip to main content
Pharmaceutical Biology logoLink to Pharmaceutical Biology
. 2020 Apr 16;58(1):306–307. doi: 10.1080/13880209.2020.1745479

Correction

PMCID: PMC7178862  PMID: 32298602

Article title: MiR-152 influences osteoporosis through regulation of osteoblast differentiation by targeting RICTOR

Authors: L. Feng, B. Xia, B.-F. Tian, & G.-B. Lu

Journal: Pharmaceutical Biology

Bibliometrics: Volume 57, Number 1, pages 586–594

DOI: http://dx.doi.org/10.1080/13880209.2019.1657153

The authors have found out that Figures 5 and 6, and the sentence starting as “However, miR-152 inhibitor + siRICTOR group showed no significant difference…” coming under the sub-section “Expression of miR-152, RICTOR and downstream proteins in osteoblasts” of the Results section have some errors that need to be rectified.

  1. The revised Figure 5 would appear as below:Inline graphic

  2. The revised Figure 6 would appear as below: Inline graphic

  3. In the sub-section “Expression of miR-152, RICTOR and downstream proteins in osteoblasts” of the Results section, the sentence “However, miR-152 inhibitor + siRICTOR group showed no significant difference in miR-152 from miR-152 inhibitor group, with significantly increased levels of RICTOR and p-Akt (s473)/Akt (all p < 0.05)” should read, “However, miR-152 inhibitor + siRICTOR group showed no significant difference in miR-152 from miR-152 inhibitor group, with significantly decreased levels of RICTOR and p-Akt (s473)/Akt (all p < 0.05).”


Articles from Pharmaceutical Biology are provided here courtesy of Taylor & Francis

RESOURCES